Cyclin-dependent kinases as a therapeutic target for stroke.
about
Explant-induced reactivation of herpes simplex virus occurs in neurons expressing nuclear cdk2 and cdk4Activation of transcription factors AP-1 and NF-kappa B in murine Chagasic myocarditisCell cycle activity of neural precursors in the diseased mammalian brainNeuroprotective and anti-inflammatory effects of the flavonoid-enriched fraction AF4 in a mouse model of hypoxic-ischemic brain injuryBir1 deletion causes malfunction of the spindle assembly checkpoint and apoptosis in yeastNeuroprotective Mechanisms Mediated by CDK5 InhibitionThe proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1Mitochondrial fragmentation in neurodegenerationDelayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke modelsInactivation of CDK/pRb pathway normalizes survival pattern of lymphoblasts expressing the FTLD-progranulin mutation c.709-1G>ARegulation of neuron survival and death by p130 and associated chromatin modifiers.Calpain activation is required for glutamate-induced p27 down-regulation in cultured cortical neuronsInhibition of cyclin-dependent kinases improves CA1 neuronal survival and behavioral performance after global ischemia in the ratRegulation of ischemic neuronal death by E2F4-p130 protein complexesCR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury.Mining DNA microarray data using a novel approach based on graph theory.The expression of cyclins in neurons of rats after focal cerebral ischemia.Aberrant cell cycle reentry in human and experimental inclusion body myositis and polymyositisCell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury.A novel dual NO-donating oxime and c-Jun N-terminal kinase inhibitor protects against cerebral ischemia-reperfusion injury in micec-Jun mediates axotomy-induced dopamine neuron death in vivo.Multiple cyclin-dependent kinases signals are critical mediators of ischemia/hypoxic neuronal death in vitro and in vivo.Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategiesThe harlequin mouse mutation downregulates apoptosis-inducing factor.Selective CDK inhibitors: promising candidates for future clinical traumatic brain injury trials.Complement: a novel factor in basal and ischemia-induced neurogenesisCell cycle molecules define a pathway required for neuron death in development and disease.Mechanistic insight into DNA damage and repair in ischemic stroke: exploiting the base excision repair pathway as a model of neuroprotection.Cell cycle activation and spinal cord injury.Cycling at the interface between neurodevelopment and neurodegeneration.Oxidative stress, cell cycle, and neurodegeneration.Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice.Neuronal cell cycle: the neuron itself and its circumstancesCell cycle molecules and vertebrate neuron death: E2F at the hub.Remote Ischemic Conditioning Alters Methylation and Expression of Cell Cycle Genes in Aneurysmal Subarachnoid Hemorrhage.Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicityActivation of retinoblastoma protein in mammary gland leads to ductal growth suppression, precocious differentiation, and adenocarcinomaRetinal degeneration depends on Bmi1 function and reactivation of cell cycle proteins.Identification of Sleep-Modulated Pathways Involved in Neuroprotection from StrokeCyclin-dependent kinases: molecular switches controlling anergy and potential therapeutic targets for tolerance.
P2860
Q24537780-8491F1C7-03CB-45EB-B998-11F5248E33FCQ24682637-92EF9D20-BDF9-41C9-8189-F9591BB4D02DQ27011457-4D6F74A4-0857-46E3-B347-3F4277D5DF92Q27331512-8347BB97-C567-4D39-A025-6B467D57520BQ27931959-86C95BBA-2A76-4A4D-9413-31AEFC8B72A9Q28082792-8C901881-7677-45CD-80C0-91F382710AFCQ28258178-1F0D0FF0-5591-4A57-8B3B-EECF2CEDBE8AQ28284588-029E568F-D06B-4106-8A06-6F64A307CE3EQ28475093-8D40DB54-EA8D-4F35-97DC-BEBD03358717Q28483833-729F82AA-7BB2-4E84-BD0D-DF00A79C3BC9Q28567953-B2D3F9C0-6B71-4E46-9F65-7ED7819426CEQ28568449-BB978773-CBBC-403A-9304-9C75DD23356FQ28583944-2A2E4698-2C40-4CD8-9DCC-38044C4DD57DQ28771402-77424186-CE7A-42F6-BCF5-3AC124E1E1E6Q30513085-202446FB-B5D7-4BF6-8B49-D49D709F8F6AQ30666895-0CC05634-2E88-4265-BC02-DADAE2B17EF9Q33320019-6140D124-0238-4863-918D-4120F8F94617Q33784450-236EC88B-B82A-4A86-8EA2-B6A05C63E035Q33852129-ACDFB01F-46DD-46DB-906F-B2761EAEDA8AQ33854008-545C0269-C99C-4743-A5A5-F1E20F48AC7AQ33949411-6CDEF19D-3A53-4B73-8B0A-CA90ADBF790DQ34047944-9D3672EA-3658-4DAF-B4BC-34BE3B46BFA0Q34147023-F654B9A5-93D6-4CB0-A1A4-8CBC7C4E892EQ34152182-15885F23-6456-4D3B-9745-CD5F4A791885Q34412771-00D60911-A9C1-4C2B-90D2-49A59B9C2662Q34500822-5A3AEF02-8D41-40DB-BDF4-A54AA9E220FDQ34602967-A5FDFD48-B1AA-4E44-84AD-6C9B9975D211Q34805983-3E4DDB7B-0518-46FC-87D8-674282CB0E89Q35006482-680DDDB7-1316-49D3-BE98-6F763F69DDE6Q35023927-48A616FA-B5E2-43F8-9092-788270CE7A05Q35086148-040632B9-AA24-4757-B39C-CD4A3062790EQ35103069-8214E6F3-0644-4479-8CEF-20B828D4A47AQ35565056-7F7D2267-4410-433C-B218-EB8B173776F5Q35597038-E1F3305D-E963-4685-9C14-7E6EC0D260A2Q35998441-A7BAEA34-5272-4C39-9510-C8A99DA8610EQ36247797-5A07BC54-5B24-4777-BB31-A56D86662C0FQ36324624-E99947B2-4E66-42AF-8C48-44B30363030FQ36616998-193BBE91-5A1A-4863-AD21-768C787DC0BFQ36744095-40C862A2-1B41-4D40-BB24-7AD4F1227EB9Q36769222-28AB58FC-27B7-4C18-8BF3-D0A3464FCD7D
P2860
Cyclin-dependent kinases as a therapeutic target for stroke.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2000
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cyclin-dependent kinases as a therapeutic target for stroke.
@en
Cyclin-dependent kinases as a therapeutic target for stroke.
@nl
type
label
Cyclin-dependent kinases as a therapeutic target for stroke.
@en
Cyclin-dependent kinases as a therapeutic target for stroke.
@nl
prefLabel
Cyclin-dependent kinases as a therapeutic target for stroke.
@en
Cyclin-dependent kinases as a therapeutic target for stroke.
@nl
P2093
P2860
P356
P1476
Cyclin-dependent kinases as a therapeutic target for stroke
@en
P2093
P2860
P304
10254-10259
P356
10.1073/PNAS.170144197
P407
P50
P577
2000-08-01T00:00:00Z